NCT06145412 is a Phase 2 clinical trial of Xevinapan in Head and Neck Cancer, sponsored by Memorial Sloan Kettering Cancer Center.

Who is sponsoring NCT06145412?

NCT06145412 is sponsored by Memorial Sloan Kettering Cancer Center.

What drugs are being tested in NCT06145412?

Interventions in NCT06145412: Xevinapan, Cisplatin, External beam.

What condition does NCT06145412 study?

NCT06145412 studies Head and Neck Cancer.

Is NCT06145412 still recruiting?

NCT06145412 is currently active, enrolled. Last updated 22 August 2025.

Last reviewed 2025-08-22 · How we verify

NCT06145412

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A Phase II Trial of Xevinapant in Combination With Post-Operative Cisplatin and Radiotherapy for High Risk Head and Neck Cancer

Active, enrolled Phase 2 Last updated 22 August 2025

What this trial tests

Phase 2 trial testing Xevinapan in Head and Neck Cancer in 4 participants. Participants enrolled and being followed up; not accepting new ones.

Timeline

16 November 2023

Primary endpoint
1 November 2026

1 November 2026

Quick facts

Lead sponsor	Memorial Sloan Kettering Cancer Center
Phase	Phase 2
Status	Active, enrolled
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	4
Start date	16 November 2023
Primary completion	1 November 2026
Estimated completion	1 November 2026
Sites	7 locations across United States

Drugs / interventions tested

Xevinapan — full drug profile →
Cisplatin (cisplatin) — full drug profile →
External beam

Conditions studied

Head and Neck Cancer — all drugs for Head and Neck Cancer →

Sponsor

Memorial Sloan Kettering Cancer Center — full company profile →

Who can join

18 and older, any sex, with Head and Neck Cancer. Patients with the condition only — healthy volunteers not accepted.

What's being measured

Primary outcomes are the specific endpoints the trial is designed to prove or disprove.

Progression Free Survival
Time frame: 12 months
Progression free survival will be defined as the time from the start of treatment to biopsyproven locoregional recurrence, distant tumor recurrence, or death. For patients without evidence of gross disease at registration, any locoregional progression will be considered a PFS event. For patients with gross disease at registration, progression-free survival will be determined based upon RECIST 1.1

Sponsor's own description

The purpose of this study is to test whether treatment with Xevinapant added to standard chemoradiation after surgery is an effective treatment for people with high-risk head and neck cancers.

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

Multifaceted Evaluation of Inhibitors of Anti-Apoptotic Proteins in Head and Neck Cancer: Insights from In Vitro, In Vivo, and Clinical Studies (Review).
Krzykawski K, Kubina R, Wendlocha D, Sarna R, et al · · 2024 · cited 2× · PMID 39458950 · DOI 10.3390/ph17101308
IAPs in cancers: molecular mechanisms, clinical prognostic value, and translational therapeutic potential.
Teng Z, Teng L, Xie J. · · 2026 · PMID 41501908 · DOI 10.1186/s12967-025-07640-7

Verify or expand the search:

Other recruiting trials for Head and Neck Cancer

Currently open trials in the same condition.

NCT07318220 — Prehabilitation Protocol for Head and Neck Cancer Patients · NA · recruiting
NCT07524114 — Study of High-Precision Evaluation of Molecular ResiduaL Disease Through a PlatfOrm for Cancer TracKing and Interception · recruiting
NCT07467083 — Development and Application of a Nurse-Led Preemptive Symptom Management Protocol for Head and Neck Cancer Patients Unde · Phase 3 · recruiting
NCT07209189 — Neoadjuvant Chemotherapy and Programmed Cell Death Protein 1(PD-1) Inhibition for Head and Neck Cancer Treatment De-esca · Phase 2 · recruiting
NCT06837480 — Photobiomodulation in Head and Neck Cancer-Related Chronic Lymphedema · NA · recruiting

Other Memorial Sloan Kettering Cancer Center trials

Trials by the same sponsor.

NCT07566377 — Cord Blood Transplantation in Children and Young Adults With Blood Cancer · Phase 2 · recruiting
NCT07507643 — A Study of Methylprednisolone in People Having Liver Surgery · Phase 3 · recruiting
NCT07483307 — A Study of the Impact of Endocrine Therapy on Surgical Outcomes in People With Breast Cancer · Phase 2 · recruiting
NCT07459673 — HERizon-Breast: A ctDNA-Guided Adaptive Study of Sequential Anti-HER2 Therapies and CNS Prophylaxis to Induce Long-Term · Phase 2 · recruiting
NCT07449195 — A Study Comparing Two Optical Coherence Tomography Devices in People With Ocular Tumors · NA · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT06145412 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Memorial Sloan Kettering Cancer Center
Last refreshed: 22 August 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06145412.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing